JANX Stock Price
Janux Therapeutics, Inc.
JANX stock price is $18.39 (-0.59% on the day), giving Janux Therapeutics, Inc. a market cap of $1.12B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
JANX Stock Overview
- Price
- $18.39
- Previous close
- $18.50
- Open
- $18.42
- Market cap
- $1.12B
- P/E ratio
- -9.9
- 52-week range
- $12.12 - $35.34
- 1-year price target
- $30.94
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSD
- MarketXLS Rank
- 66
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JANX | $18.39 | -0.6% | 1.17M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Janux Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW